Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Affinergy Inc.

Latest From Affinergy Inc.

Bioactive Technologies For Bone Replacement

Expanded indications for bone morphogenetic proteins and new alternatives to those first-generation bone growth factors have the potential to grow the $2 billion market for bone replacement materials. This article is reprinted from the April 2010 issue of Medtech Insight (Also see "Bioactive Technologies for Bone Replacement" - Medtech Insight, 1 Apr, 2010.).

Bioactive Technologies for Bone Replacement

The global market for orthobiologics, comprised primarily of bone replacement materials, reached almost $2 billion in 2009 and is growing at an overall rate of 7%. Medtronic leads in bone replacement with a 45% market share, but overall growth in orthobiologics may come from emerging segments, particular synthetic and stem-cell based technologies.
Medical Device

Nothing Ventured, Something Gained

A growing number of medical device start-ups are using a variety of strategies-angel investors, government grants, and corporate partners-to go all the way to commercialization or exit without relying on venture capital funding. The trend away from venture financing is gaining advocates, particularly among device start-ups with unconventional business models or products that play in small market niches. In the process, these new financing models are giving small device companies who have been turned down by VCs or found their terms difficult to swallow, some hope.
Medical Device Business Strategies

Biocoatings: Not Just the Icing on the Cake

The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.
Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Biosensors
  • Medical Devices
    • Biomaterials
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Therapeutic Areas
  • Cardiovascular
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Affinergy Inc.
  • Senior Management
  • Peyton Anderson, CEO
    Jonathan Gindes, VP, Operations & Fin.
    Bruce S Lamb, PhD, SVP, R&D
  • Contact Info
  • Affinergy Inc.
    Phone: (919) 433-2200
    617 Davis Dr.
    Ste. 100
    Durham, NC 27713